Myelofibrosis Pipeline Drugs Analysis Report, 2023: Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Companies - Incyte Corporation, AbbVie, Keros Therapeutics, Inc., Pharmaxis, Novartis, Galecto Biotech AB, Activ

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myelofibrosis pipeline constitutes 7+ key companies continuously working towards developing 8+ Myelofibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Myelofibrosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.

The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myelofibrosis Pipeline Report: https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years. Myelofibrosis Key players such as - Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, Keros Therapeutics, Inc., Pharmaxis, Novartis, Galecto Biotech AB, and others, are developing therapies for the Myelofibrosis treatment
• Myelofibrosis Emerging therapies such as - Tasquinimod, HC-X027, ABBV-744, IOA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, KER-050 monotherapy, PXS-5505, Ruxolitinib, GB2064, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.
• In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology's proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis
• In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 36% of patients, and dysgeusia led to discontinuation in 1 patient. There were 14 serious adverse events (SAEs) deemed related to bomedemstat per the Investigator.
• In May 2022, Active Biotech announced that US FDA has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis
• In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes
• In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis
• In April 2021, Geron Corporation initiated a randomized open-label, Phase III study to evaluate Imetelstat (GRN163L) versus Best Available Therapy (BAT) in patients with intermediate-2 or high-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor

Myelofibrosis Overview
Myelofibrosis is a rare disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases.

Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:
• Tasquinimod: Active Biotech
• HC-X027: Hinova Pharmaceuticals
• ABBV-744: AbbVie
• IOA-244: iOnctura
• TP-3654: Sumitomo Pharma Oncology
• PXS-5505: Pharmaxis
• KER-050: Keros Therapeutics
• NS-018: Nippon Shinyaku
• Parsaclisib: Incyte Corporation
• Pelabresib: MorphoSys
• Imetelstat: Geron Corporation
• KER-050 monotherapy: Keros Therapeutics, Inc.
• PXS-5505: Pharmaxis
• Ruxolitinib: Novartis
• GB2064: Galecto Biotech AB

Route of Administration
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Myelofibrosis Pipeline Therapeutics Assessment
• Myelofibrosis Assessment by Product Type
• Myelofibrosis By Stage and Product Type
• Myelofibrosis Assessment by Route of Administration
• Myelofibrosis By Stage and Route of Administration
• Myelofibrosis Assessment by Molecule Type
• Myelofibrosis by Stage and Molecule Type

DelveInsight's Myelofibrosis Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies at: https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Myelofibrosis Therapeutics Market include:
Key companies developing therapies for Myelofibrosis are - Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., Constellation Pharmaceuticals, Kartos Therapeutics, Inc., NS Pharma, Inc., Nippon Shinyaku Co., Ltd., Geron Corporation, Inc., Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Hoffmann-La Roche, Lynk Pharmaceuticals Co., Ltd, Chengdu Zenitar Biomedical Technology Co., Ltd, Prelude Therapeutics, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, The Menarini Group, Cyclica Inc, GAT Therapeutics, Hinova pharmaceuticals, iOnctura, Telios Pharma, Inc. and many others.

Myelofibrosis Pipeline Analysis:
The Myelofibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
• Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myelofibrosis drugs and therapies- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myelofibrosis Pipeline Market Drivers
Increase in R&D for the development of new and effective drugs for the treatment, Increasing incidence in Elderly Population, and development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Pipeline Market Barriers
However, side effects associated with the drugs, high cost of Myelofibrosis therapy and other factors are creating obstacles in the Myelofibrosis Market growth.

Scope of Myelofibrosis Pipeline Drug Insight
• Coverage: Global
• Key Myelofibrosis Companies: Active Biotech, Hinova Pharmaceuticals, AbbVie, iOnctura, Sumitomo Pharma Oncology, Pharmaxis, Keros Therapeutics, Nippon Shinyaku, Incyte Corporation, MorphoSys, Geron Corporation, Keros Therapeutics, Inc., Pharmaxis, Novartis, Galecto Biotech AB, and others
• Key Myelofibrosis Therapies: Tasquinimod, HC-X027, ABBV-744, IOA-244, TP-3654, PXS-5505, KER-050, NS-018, Parsaclisib, Pelabresib, Imetelstat, KER-050 monotherapy, PXS-5505, Ruxolitinib, GB2064, and others
• Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
• Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers

Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Myelofibrosis Report Introduction
2 Myelofibrosis Executive Summary
3 Myelofibrosis Overview
4 Myelofibrosis- Analytical Perspective In-depth Commercial Assessment
5 Myelofibrosis Pipeline Therapeutics
6 Myelofibrosis Late Stage Products (Phase II/III)
7 Myelofibrosis Mid Stage Products (Phase II)
8 Myelofibrosis Early Stage Products (Phase I)
9 Myelofibrosis Preclinical Stage Products
10 Myelofibrosis Therapeutics Assessment
11 Myelofibrosis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Myelofibrosis Key Companies
14 Myelofibrosis Key Products
15 Myelofibrosis Unmet Needs
16 Myelofibrosis Market Drivers and Barriers
17 Myelofibrosis Future Perspectives and Conclusion
18 Myelofibrosis Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Myelofibrosis Market https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myelofibrosis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Myelofibrosis Epidemiology https://www.delveinsight.com/report-store/myelofibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myelofibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.